<DOC>
	<DOC>NCT00578097</DOC>
	<brief_summary>The purpose of this study is to determine the optimal dose of botulinum toxin type A injected in the detrusor muscle to improve urinary symptoms, urodynamic parameters and quality of life of continent women suffering from idiopathic overactive bladder.</brief_summary>
	<brief_title>Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>The subject has a diagnosis of idiopathic overactive bladder, without incontinence. The subject has ≥ 3 urgency episodes over the course of the 3 days immediately preceding the Baseline visit. The subject has ≥ 24 episodes of micturition over the course of the 3 days immediately preceding the Baseline visit. Bladder outlet obstruction (on urodynamic assessment). PostMicturition Residual Volume &gt; 150 ml (ultrasound assessment). Evidence of a urinary tract infection at Screening or Baseline in the study. Active or history of interstitial cystitis, malignancy of the bladder or urothelial tract, a carcinoma in situ (non malignant melanoma is allowed) bladder and/or kidney stones.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>